Banco BTG Pactual S.A. Purchases New Stake in DexCom, Inc. $DXCM

Banco BTG Pactual S.A. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,345 shares of the medical device company’s stock, valued at approximately $1,350,000.

Other hedge funds have also recently bought and sold shares of the company. Gradient Investments LLC grew its position in DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after acquiring an additional 40,343 shares in the last quarter. Nordea Investment Management AB grew its position in DexCom by 118.6% in the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after acquiring an additional 137,986 shares in the last quarter. NEOS Investment Management LLC grew its position in DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after acquiring an additional 65,066 shares in the last quarter. Banco Santander S.A. grew its position in DexCom by 28.9% in the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after acquiring an additional 56,062 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its position in DexCom by 58.2% in the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock valued at $7,289,000 after acquiring an additional 40,411 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 42,694 shares of company stock worth $3,029,267 over the last three months. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Up 0.6%

DXCM stock opened at $75.25 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $29.04 billion, a P/E ratio of 32.16, a PEG ratio of 1.17 and a beta of 1.45. The firm has a 50 day simple moving average of $65.87 and a 200-day simple moving average of $67.50.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company earned $0.32 earnings per share. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities research analysts predict that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial reaffirmed a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research report on Friday, May 1st. Mizuho set a $85.00 price objective on shares of DexCom and gave the company an “outperform” rating in a research report on Tuesday. Finally, Robert W. Baird set a $80.00 price objective on shares of DexCom in a research report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.29.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.